Drugs / ESR1 peptide vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04270149 | Sep 2020 → May 2025 overdue | breast cancer | Herbert Lyerly | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ESR1 peptide vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04270149 ↗ |
| Modality | Vaccine | “The primary objective of the study is to determine the safety of of the peptide vaccine.” NCT04270149 ↗ |